MX2018016183A - Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. - Google Patents

Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.

Info

Publication number
MX2018016183A
MX2018016183A MX2018016183A MX2018016183A MX2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A
Authority
MX
Mexico
Prior art keywords
methods
antibodies
same
fragments
specific antibodies
Prior art date
Application number
MX2018016183A
Other languages
English (en)
Inventor
Belk Jonathan
J Sharkey Nathan
Gorelik Leonid
Original Assignee
Checkpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkpoint Therapeutics Inc filed Critical Checkpoint Therapeutics Inc
Publication of MX2018016183A publication Critical patent/MX2018016183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente descripcion se refiere generalmente a anticuerpos y fragmentos de union funcionales de los mismos que se unen al ligando 1 de muerte programada (PD-L1); en particular, los anticuerpos y fragmentos descritos se unen al PD-L1 de humano, y comprenden regiones determinantes de complementariedad (CDRs) novedosas; finalmente, la presente descripcion se refiere a administrar los anticuerpos y fragmentos descritos a sujetos con cancer, de esta manera tratando o retardando la progresion o proliferacion del cancer.
MX2018016183A 2016-06-29 2017-06-28 Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. MX2018016183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356105P 2016-06-29 2016-06-29
PCT/US2017/039810 WO2018005682A2 (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
MX2018016183A true MX2018016183A (es) 2019-06-10

Family

ID=60785529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016183A MX2018016183A (es) 2016-06-29 2017-06-28 Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.

Country Status (13)

Country Link
US (3) US10590199B2 (es)
EP (1) EP3478723A4 (es)
JP (2) JP7148414B2 (es)
KR (2) KR102422411B1 (es)
CN (1) CN109641960A (es)
AU (1) AU2017290709A1 (es)
BR (1) BR112018076684A2 (es)
CA (1) CA3027204A1 (es)
IL (2) IL263611B (es)
MX (1) MX2018016183A (es)
RU (1) RU2749109C2 (es)
SG (2) SG10202100100UA (es)
WO (1) WO2018005682A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US10590199B2 (en) * 2016-06-29 2020-03-17 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
IL296408A (en) 2018-10-31 2022-11-01 Immunitybio Inc Elimination of PD-11-positive malignancies by NK cells expressing a chimeric antigen receptor for PD-11
KR102207478B1 (ko) * 2019-03-13 2021-01-26 한국도로공사 시간 정보를 활용한 톨링 시스템 및 그의 구동 방법
JP7212990B2 (ja) 2019-04-26 2023-01-26 アイ－エムエービー バイオファーマ ユーエス リミテッド ヒトｐｄ‐ｌ１抗体
EP3976090A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
CN113121686A (zh) * 2019-12-31 2021-07-16 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN103172737A (zh) 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2627890A1 (en) * 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
KR101573109B1 (ko) * 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
LT2785375T (lt) * 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
CN115093480A (zh) * 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN106029098A (zh) * 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
KR20170090506A (ko) 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
CA2978942A1 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
IL260530B2 (en) * 2016-01-11 2024-01-01 Inhibrx Inc Multispecific and multivalent 41BB-binding fusion proteins, preparations containing them and their uses
RU2022104399A (ru) * 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
US10590199B2 (en) * 2016-06-29 2020-03-17 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
CN110191720A (zh) * 2016-09-09 2019-08-30 Tg治疗有限公司 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合

Also Published As

Publication number Publication date
KR20220004763A (ko) 2022-01-11
JP2019532013A (ja) 2019-11-07
US11834505B2 (en) 2023-12-05
BR112018076684A2 (pt) 2019-04-02
US10590199B2 (en) 2020-03-17
US20200277380A1 (en) 2020-09-03
JP7148414B2 (ja) 2022-10-05
WO2018005682A2 (en) 2018-01-04
EP3478723A4 (en) 2020-07-29
IL276515A (en) 2020-09-30
KR20190028716A (ko) 2019-03-19
US20240150468A1 (en) 2024-05-09
AU2017290709A1 (en) 2019-01-24
CN109641960A (zh) 2019-04-16
SG11201810927QA (en) 2019-01-30
KR102422411B1 (ko) 2022-07-18
RU2749109C2 (ru) 2021-06-04
JP2022120008A (ja) 2022-08-17
IL263611B (en) 2020-08-31
EP3478723A2 (en) 2019-05-08
US20180002424A1 (en) 2018-01-04
CA3027204A1 (en) 2018-01-04
RU2019102009A (ru) 2020-07-28
SG10202100100UA (en) 2021-02-25
IL263611A (en) 2019-01-31
RU2019102009A3 (es) 2020-12-14
WO2018005682A3 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
NZ739499A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
NZ738008A (en) Tigit-binding agents and uses thereof
WO2018031490A3 (en) Anti-ox40 binding proteins
PH12020552229A1 (en) Il-11ra antibodies
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2018005830A (es) Composiciones y metodos para tratar enfermedades autoinmunes y canceres.
AU2024202102A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
EP3733703A4 (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment
MX2020008122A (es) Anticuerpos anti-pd-1.
WO2018069871A3 (en) Anti-kras binding proteins
MX2015008117A (es) Anticuerpos anti-h7cr.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.